We take a look at some of the COVID-19 vaccine candidates moving through Phase 1 and 2 clinical trials – and how they could offer a point of difference to authorized vaccines. While vaccines from big names such as Pfizer/BioNTech, Moderna and AstraZeneca are rolling out across the world, there are currently 64 vaccines in […]

Dr. Caroline Loew, President and CEO of Glympse Bio, a clinical stage biotechnology company, discusses the company’s development of tunable biosensors capable of noninvasive disease monitoring in NASH, other fibrotic diseases, and Non-Small Cell Lung Cancer. They serve as a repeatable alternative to biopsy, allowing patients to be monitored more frequently without the need for […]

Dr. Jonathan Javitt, Founder, Chairman and CEO, NeuroRx talks about drawing on their work developing novel therapeutics for bipolar depression and respiratory disease to focus on a therapy, aviptadil also known as ZYESAMI, for critical COVID-19 especially those with advanced comorbidities. This peptide hormone VIP enters the alveolar type II rare cell in the lung […]